Every peptide resource on the internet today is a storefront with a literature review bolted to the front of it. When you search for a peptide, the top results are affiliate wikis and vendor blogs — written by people who make money when you buy.
This is different. We make zero dollars when you do anything. We are funded by grants and public foundations only. We answer three questions, and only these three:
Evidence
What is the actual evidence that it does anything in humans? Evidence tier (E1–E8) displayed prominently on every page.
Regulatory Status
Is it approved? In which jurisdictions? Is it investigational? All regulatory claims cited to primary sources (FDA, EMA, etc.).
Purity
If you obtained it on the gray market, what is actually in the vial? Annual purity testing programme, vendors named.
The Evidence Tier System
Every compound is positioned on the same eight-step scale. No exceptions. The scale runs from established evidence (E1) to no evidence at all (E8).
E1: Multiple RCTs, consistent results | E2: One RCT | E3: Small/conflicting RCTs | E4: Uncontrolled trials | E5: Case series | E6: Animal models | E7: In vitro | E8: No evidence
Three Classes of Peptides
Peptides with regulatory approval in at least one major jurisdiction. Standard drug monographs: indications, approved doses (from the label), pivotal trials, safety profile.
Examples: semaglutide (Ozempic), tirzepatide (Mounjaro), teriparatide (Forteo), bremelanotide (Vyleesi)
Governance & Transparency
All Editorial Decisions Have a Signature
Every compound record is reviewed by a named editor, dated. Corrections are logged publicly. Funding is disclosed. We are funded by grants and public foundations only — zero dollars from vendors.
Purity Testing Programme
Gray-market peptides are purchased blindly from retail vendors, tested by independent labs (LC-MS/MS for identity and purity, endotoxin, sterility), and results are published with vendor names. This is primary data, not aggregation — the only thing on this topic that can't be copied by affiliate sites because it requires actually buying the stuff and running the assays.
Annual purity surveys per compound class: Results published here and in peer-reviewed journals.
Start Here
- Read the boundaries — what we will and won't tell you, and why
- Browse all compounds — sorted by evidence tier
- See an example (Class B) — retatrutide, the most-discussed investigational GLP-1 agonist
- See an example (Class C) — BPC-157, marketed on E6 animal evidence, sold as E8 gray market